Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies-Reference-Cited by-同舟云学术

Comparison of RT-qPCR and Nanostring in the measurement of blood interferon response for the diagnosis of type I interferonopathies

Published:2019-01 Issue: Volume:113 Page:446-452
ISSN:1043-4666
Container-title:Cytokine
language:en
Short-container-title:Cytokine

Author:

Pescarmona Rémi,Belot Alexandre,Villard Marine,Besson Laurie,Lopez Jonathan,Mosnier Isabelle,Mathieu Anne-Laure,Lombard Christine,Garnier Lorna,Frachette Cécile,Walzer Thierry,Viel Sébastien

Funder

FINOVI foundation, Agence Nationale de la Recherche, European Research council

INSERM, CNRS, Université de Lyon, and ENS de Lyon

Publisher

Elsevier BV

Subject

Molecular Biology,Hematology,Biochemistry,Immunology,Immunology and Allergy

Reference39 articles.

1. Virus interference. I;Isaacs;The interferon. Proc. R Soc. Lond, B, Biol. Sci.,1957

2. Interferons, interferon-like cytokines, and their receptors;Pestka;Immunol. Rev.,2004

3. Disease mechanisms in rheumatology–tools and pathways: plasmacytoid dendritic cells and their role in autoimmune rheumatic diseases;Eloranta;Arthritis Rheum.,2013

4. Recognition of nucleic acids by pattern-recognition receptors and its relevance in autoimmunity;Kawasaki;Immunol. Rev.,2011

5. RIG-I-like receptors: cytoplasmic sensors for non-self RNA;Kato;Immunol. Rev.,2011

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges and opportunities in processing NanoString nCounter data;Computational and Structural Biotechnology Journal;2024-12

2. Hereditary C1q Deficiency is Associated with Type 1 Interferon-Pathway Activation and a High Risk of Central Nervous System Inflammation;Journal of Clinical Immunology;2024-08-28

3. Neurological Impact of Type I Interferon Dysregulation;Rare Neurodegenerative Disorders - New Insights [Working Title];2024-07-31

4. The Impact of TLR9 Expression Loss on Breast Cancer Tumor Cells;2024-07-06

5. JAK inhibitors in refractory juvenile rheumatic diseases: Efficacy, tolerance and type-I interferon profiling, a single center retrospective study;Journal of Autoimmunity;2024-07